Publication Name	World Journal of Diabetes
Manuscript ID	66636
Country	Türkiye

Received	2021-03-31 19:40
Peer-Review Started	2021-03-31 19:49
First Decision by Editorial Office Director	2021-06-05 02:39
Return for Revision	2021-06-05 02:39
Revised	2021-06-19 17:57
Publication Fee Transferred
Second Decision by Editor	2021-12-20 03:27
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-12-23 06:18
Articles in Press	2021-12-23 06:18
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-01-05 13:06
Publish the Manuscript Online	2022-01-11 06:48

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Acarbose is again on the stage
Manuscript Source	Invited Manuscript
All Author List	Mustafa Altay
Funding Agency and Grant Number
Corresponding Author	Mustafa Altay, MD, Chairman, Professor, Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Keçiören Health Administration and Research Center, Pınarbaşı District, Ardahan St. No. 25, Keçiören 06290, Ankara, Türkiye. mustafa.altay@sbu.edu.tr
Key Words	Acarbose; Cardiovascular protection; Glucagon-like peptide 1; Obesity; Waist-to-height ratio
Core Tip	The prevention of obesity and reducing cardiovascular risks, together with blood glucose control in patients with type 2 diabetes, are the main components of the treatment’s goals. New studies show that acarbose can provide the expected benefits of an ideal antidiabetic drug by increasing both insulin sensitivity and glucagon-like peptide 1 levels.
Publish Date	2022-01-11 06:48
Citation	Altay M. Acarbose is again on the stage. World J Diabetes 2022; 13(1): 1-4
URL	https://www.wjgnet.com/1948-9358/full/v13/i1/1.htm
DOI	https://dx.doi.org/10.4239/wjd.v13.i1.1

Full Article (PDF)	WJD-13-1.pdf
Full Article (Word)	WJD-13-1.docx